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Summary Etoposide phosphate is a water-soluble prodrug of etoposide. It was expected that this prodrug could be used to overcome the
solubility limitations and erratic bioavailability of oral etoposide. To investigate the possibility of prodrug conversion to etoposide within the
gastrointestinal lumen, etoposide phosphate was dissolved in water and incubated with human gastric juice or human bile in vitro. Samples
were collected during 150 min and analysed foretoposide concentration with high-performance liquid chromatography. Conversion ofprodrug
to etoposide during incubation with gastric juice was negligible. There was significant conversion during incubation with bile at pH 7-8. The
percentage of prodrug converted to etoposide at pH 8 after 60 min was 78 ± 18% (mean ± S.D.) for a 0.1 mg ml-' prodrug solution and
36 ± 26% for 0.5 mg ml-'. At pH 7, after 60 min 22% of prodrug was converted to etoposide when incubated at 0.1 mg ml-' and 10% at
0.5 mg ml-'. No conversion was found after inactivation of alkaline phosphate (AP) by overnight heating of bile at 650C or by the addition of
disodium edetate to the bile. In conclusion, because of AP in bile, variable conversion of etoposide phosphate to etoposide can be expected
within the intestinal lumen after oral administration. This could have important pharmacokinetic consequences.
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Etoposide, a semisynthetic podophyllotoxin, is an effective anti-
cancerdrug, andoral administration is attractive because ofpatient
convenience and the remarkable activity of oral etoposide in
several malignancies (deJong et al., 1995). However, the bioavail-
ability oforal etoposide is erratic: it decreases considerably below
50% for doses above 200 mg and shows wide inter- and intrapa-
tient variability (Harvey et al., 1985; Slevin et al., 1989; Hande et
al., 1993). This is probably because of the low aqueous solubility
and slow intrinsic dissolution rate ofetoposide (Shah et al., 1989).
The consequences are considerable risks of underdosing and
unpredictable toxicity.
Recently, etoposide phosphate, a prodrug of etoposide charac-
terized by a phosphate group in position 4' of the E-ring of the
etoposide molecule, was synthesized (Saulnier et al., 1994).
Because this prodrug is considerably more water-soluble, oral
administration was expected to result in improved etoposide
plasma pharmacokinetics compared with orally administered
etoposide. However, in a comparative pharmacokinetic study, we
found only minor improvement ofbioavailability and wide varia-
tion in etoposide plasma concentrations (de Jong et al., 1997). In
addition, the prodrug was never detectable in plasma after oral
administration (de Jong et al., 1997; Sessa et al., 1995). These
observations suggested that the prodrug was possibly converted to
etoposide within the gastrointestinal lumen. A potential cause is
alkaline phosphatase (AP), which is present in bile and enzymes
present in gastric or intestinal juices. Therefore, the extent of
etoposide phosphate conversion to etoposide during in vitro
incubation with human gastricjuice or bile was studied.
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MATERIALS AND METHODS
Bile and gastric juice
Bile (samples of ± 50 ml, pH 7.7-8.5) was collected from five
patients who had biliary drains. Two patients had a distal biliary
stenosis (one with pancreatic carcinoma and one with benign
biliary stenosis) and three were post-liver-transplantation patients.
Because oral etoposide phosphate was administered to fasted
patients in pharmacokinetic studies, gastric juice was collected
after overnight fasting. The specimens (15-20 ml, pH 1.29-1.76)
were obtained when suction was performed during a diagnostic
gastroscopy in two individuals. The patients had not used acid-
suppressive agents and gastroscopy had not revealed any abnor-
malities. All subjects gave informed consent. The bile and gastric
juice samples were transferred to 5-ml polyethylene tubes, frozen
in liquid nitrogen and then stored at -20°C. For experiments,
frozen samples were thawed and warmed for 2 h at 37°C to enable
recovery of enzyme activity. Experiments comparing etoposide
phosphate conversion to etoposide, as described below, with both
fresh bile and bile from the same sample that had been frozen and
thawed according to this procedure yielded similar results.
Etoposide phosphate
Etoposide phosphate (kindly provided by Bristol-Myers Squibb,
Wallingford, CT, USA) was dissolved in water. The total volume,
including gastric and duodenal content, in which the dose is
dispersed can only be roughly estimated. Oral doses in clinical
studies range between 50 and 450 mg (100 mg etoposide phos-
phate is molar equivalent to 88 mg etoposide). Etoposide phos-
phate is administered as capsules and these are usually swallowed
with 100-200 ml water. In the gastric lumen, concentrations of
± 0.5-1 mg ml-1 etoposide phosphate would be expected for doses
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of 100-200 mg etoposide phosphate administered orally with
150 ml water, assuming that usually 25-30 ml offluid is present in
the stomach after fasting (Shevde and Trivedi, 1991). Further dilu-
tion is expected within the intestinal lumen. Based on these esti-
mations, a wide range of concentrations was chosen for the
incubation experiments (0.03-3 mg ml-1). The percentage of
etoposide phosphate converted to etoposide after incubation was
calculated by dividing the resulting etoposide concentration by the
etoposide molar equivalent of the etoposide phosphate concentra-
tion at the start ofincubation.
Incubation of etoposide phosphate in gastric juice
The etoposide concentration was measured in samples obtained 0,
30, 60,90 and 150 min after the start ofincubation at 37°C of 3 ml
of etoposide phosphate in water solution mixed with 3 ml of
gastric juice. The etoposide phosphate concentrations in the
mixture at the start of the incubation were 0.5 and 1 mg ml-'. The
gastric juice oftwo individuals was used and each experiment was
performed in triplicate. The stability of etoposide (Bristol-Myers
Squibb) was studied in the same design with a final etoposide
concentration of0.25 mg ml-I.
Incubation of etoposide phosphate in bile
The stability of etoposide phosphate was tested over a wide range
ofconcentrations and at different pH with bile from the patient with
benign biliary stenosis, from whom a large bile volume (120 ml)
was obtained. To 3 ml ofetoposide phosphate solution, 3 ml ofbile
and 3 ml of phosphate buffer 0.01 mol 1-1 were added, resulting in
final etoposide phosphate concentrations in the mixture of 0.03,
0.1, 0.25, 0.5, 1, 2.5 and 3 mg ml-1 at the start of the incubation
period. The phosphate buffer was adjusted to pH 8 with 10% phos-
phoric acid. The solutions were mixed and then incubated at 37°C.
Samples for the determination of conversion to etoposide were
collected 0, 5, 10, 20, 30, 45, 60, 90, 120 and 150 min after the
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Figure 1 Etoposide formation during incubation of etoposide phosphate in
bile from one individual, at pH 8 and 370C, over 150 min. The etoposide
phosphate concentration, in mg ml-', at the start of incubation is shown at the
end of each curve. Conversion of etoposide phosphate to etoposide
decreased at concentrations above 0.5 mg ml-'
addition ofbile. Because AP activity is pH dependent and duodenal
pH is variable between pH 5 and 8 beyond the duodenal
bulb (Davenport, 1977), incubation experiments with 0.1 and
0.5 mg ml-l etoposide phosphate were also performed at pH 5,
pH 6, pH 7 and pH 8 (at 37°C). To study interindividual variability,
similar experiments were performed with bile samples from all five
patients with 0.1 and 0.5 mg ml-'etoposide phosphate at pH 8. The
AP activity of each bile sample was also determined, according to
the International Federation for Clinical Chemistry recommenda-
tions, at 37°C using a routine clinical chemical analyser (Ektachem,
Johnson & Johnson, Beerse, Belgium). In addition, the stability
of etoposide at 0.25 mg ml-1 was tested in the same design as
described above for etoposide phosphate. This etoposide concen-
tration was based on the maximum concentration of etoposide
found after incubation of etoposide phosphate with bile in the
previous experiments. Thereafter, it was studied whether the
conversion of etoposide phosphate to etoposide was due to enzy-
matic activity. To investigate this, similarly designed incubation
experiments, starting with 0.1 mg ml-' etoposide phosphate, were
performed with bile heated overnight at 65°C and bile to which
2.2 mmol 1-1 disodium edetate (EDTA) was added. This EDTA
concentration was based on the Ca2+ and Mg2+ concentrations in the
bile sample (1.57 and 0.5 mmol 1-l respectively). EDTA binds Ca2+
and Mg2+ and AP activity is dependent on these ions (Moss et al.,
1986). All experiments were performed in triplicate and results
were reported as the means from the three separate measurements
(the variability was within 10% for all experiments).
Analysis of etoposide concentration
Bile and gastric juice samples to which etoposide phosphate
solution was added were assayed immediately. The etoposide
concentration was determined using high-performance liquid chro-
matography (HPLC) with UV detection. The assay was based on
the method described by Holthuis et al (1981) for determination of
etoposide in urine and plasma, with teniposide as internal standard.
To a sample of0.5 ml, 100 ,ul ofa stock solution of 1.23 g 1-1 teni-
poside (Bristol-Myers Squibb) was added before extraction with
4 ml of chloroform (Merck, Darmstadt, Germany). After 5 min of
centrifugation at 1500g, the aqueous bile/gastric juice layer was
removed and the organic layer was washed three times with 1 ml of
0.01 M phosphate buffer (pH 7.3). The organic layer was dried
under nitrogen gas at ambient temperature and the residue was
reconstituted in 200 pl of the mobile phase solution. Then, 50 pl
was injected onto a Lichrosorb RP-18 5-pm HPLC column, 250 x
4.0 mm ID (Merck). The mobile phase was a methanol plus water
(50 ml + 49 ml) solution (at pH 3.3 with acetic acid) at a flow rate
of 1.3 ml min-'. A UV-spectrophotometer (Spectroflow 757, ABI
Analytical Kratos Division, Ramsey, NJ, USA) at280 nm was used
as detector. Quantification was performed using the peak height
ratio of etoposide to internal standard. The concentrations were
calculated on a calibration curve, using spiked bile plus water and
0.01 M phosphate buffer (= 1+1+1) or spiked gastric juice plus
water (= 1+1). The calibration curves were linear at least over the
range 0.05-0.25 mg ml-' with a correlation coefficient of> 0.99.
The lower limit of detection of etoposide (defined as the lowest
concentration with a CV <20%) was 0.001 mg ml-1. The extraction
efficiency of etoposide was 98.6 ± 2.0% (0.1 mg ml-', n = 6). For
concentrations expected to exceed the upperlimit ofthe calibration
curve, determination was performed after two- to five-fold dilution
with deionized water. To avoid differences in recovery, bile or
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gastric juice solutions of the calibration curve were diluted before
spiking with etoposide. Quality control (QC) bile or gastric juice
samples containing etoposide (0.1 mg ml-1), were prepared and
assayed each time with the experimental samples. The accuracy of
the QC samples was within 6.1% of the nominal value and the
between-day and within-day precision were within 2.7% relative
standard deviation.
RESULTS
Conversion of etoposide phosphate to etoposide in
gastric juice
Less than 0.5% conversion to etoposide was found during incuba-
tion ofetoposide phosphate with gastricjuice. Etoposide itselfwas
also stable under the same conditions as 94% could be recovered
after 150 min.
Conversion of etoposide phosphate to etoposide in bile
As shown in Figure 1, the etoposide concentration rapidly
increased during incubation ofetoposide phosphate in bile at pH 8,
implicating dephosphorylation ofthe prodrug. Some etoposide was
already found in samples taken immediately after the start ofincu-
bation (0 min). Asetoposide itselfwas stable inbile (< 5% decrease
in concentration during 150 min incubation at pH 5-8) and as the
extraction was almost 100%, the resulting etoposide concentrations
could be used to calculate the percentage ofprodrug conversion. At
the lowest etoposide phosphate concentrations, 0.03 mg ml-' and
0.1 mg ml-', over 85% conversion was found within 60 min. The
resulting amount ofetoposide decreased with etoposide phosphate
concentrations over0.5 mg ml-', suggesting that the enzyme poten-
tially becomes saturated at high etoposide phosphate concentra-
tions (Figure 1). Mean (± s.d.) percent conversion at etoposide
phosphate concentrations of0.1 mg ml-' and 0.5 mg ml-' in experi-
ments with bile samples from five different individuals is shown in
Figure 2. The conversion to etoposide after 60 min ranged from
43% to 94% for 0.1 mg ml- etoposide phosphate and from 6% to
74% for 0.5 mg ml-' etoposide phosphate. This indicates consider-
able interindividual variation. The bile AP activity ofbile samples,
according to routine clinical chemical analysis, also showed a wide
interindividual variation (384, 432, 833, 919 and 2172 U 11).
Conversion was found to be pH dependent and almost completely
absent at pH <6 (Figure 3). At pH 7, there was still a 50% conver-
sion in the 0.1 mg ml-' solution after 150 min. No conversion was
observed afterheating the bile at 65°C or in the presence ofEDTA.
These findings and the inhibition ofconversion at acid pH indicate
that AP in the bile was responsible for the conversion ofetoposide
phosphate to etoposide.
DISCUSSION
In the present in vitro study, negligible conversion of the prodrug
etoposide phosphate to etoposide was found during incubation
with human gastric juice. The ratio of gastric juice to etoposide
phosphate was arbitrary (1:1) but chosen to represent excess
gastricjuice, and similarresults are expected with smaller amounts
of gastric juice. Etoposide itself was stable in the gastric juice
samples for at least 1.5 h. Joel et al. (1995) reported degradation of
etoposide incubated for longer than 2 h at pH 1 in artificial gastric
fluid. This indicates that the stability of etoposide, and etoposide
phosphate, might be less when administered with meals, because
food stimulates acid secretion and delays gastric emptying.
However, the present in vitro experiments do not show that the
gastric phase is of major influence on the etoposide pharmaco-
kinetics after oral etoposide phosphate compared with oral etopo-
side. Factors present in the intestinal lumen are probably more
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Figure 2 Mean (± s.d.) percentage conversion of etoposide phosphate to
etoposide over 150 min in bile at pH 8 and 370C (n = 5). (A) Etoposide
phosphate concentration at start of incubation = 0.1 mg ml-l; (B) 0.5 mg mi-'
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Figure 3 Conversion of etoposide phosphate to etoposide (%) over 150
min in bile at different pH values. (A) Etoposide phosphate concentration at
start of incubation = 0.1 mg ml-'; (B) 0.5 mg ml-'
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important. A significant conversion of prodrug to etoposide was
observed after incubation with human bile. AP in the bile was
found tobe responsible forthisphenomenon. The latterconclusion
ofthe present study is based on indirect evidence, but others have
shown that etoposide is rapidly converted to etoposide by AP in
vitro (Senter et al, 1988).
The results ofthis in vitro study allow some quantitative estima-
tions ofthe effects expected in vivo. The predicted initial prodrug
concentration in the intestinal lumen afteranoraldoseof 100mg of
etoposide phosphate, administered with 100-200 ml of water, is
+ 0.5 mg ml-'. At this concentration and assuming similar condi-
tions as used in vitro, about 36% of the prodrug is converted to
etoposide within 1 h at pH 8. Fallingborg et al (1989) showed that
the mean pH in the duodenum is 6.4 and rises to 7.3 in the distal
small intestine. In the present study, 10% of the prodrug was
converted after 1 h at pH 7 (at 0.5 mg ml-'). Because the maximal
incubation time in our experiments was shorter than the median
total small intestinal transit time of8 h (Fallingborg et al., 1989), it
is possible that these percentages underestimate the in vivo situa-
tion. Our results also indicate that the percentage conversion may
be higher when low prodrug doses (e.g. 50-100 mg) are adminis-
tered. Less conversion occurred at high prodrug concentrations.
This might indicate that AP becomes saturated when large etopo-
side phosphate doses (more than 200-300 mg) are administered. In
contrast, such an effect wouldbe counteracted by the decline ofthe
intestinal prodrug concentration because ofabsorption and dilution.
In conclusion, the advantage of the oral administration of the
prodrug etoposide phosphate, compared with oral etoposide, is
probably less than expected because the prodrug is affected by AP
in the bile. The possibility of increased conversion of etoposide
phosphate to etoposide should be considered in patients who
receive concomitant acid suppressive medication because AP
activity increased at high intestinal pH. In contrast, AP activity
might be reduced when the prodrug is administered together with
acid beverages, such as cola and lemonjuice. It is also tempting to
consider coadministration of AP inhibitors. This knowledge can
also be of value for the development of other oral (pro-) drugs
incorporating phosphate groups.
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